RecruitingNot ApplicableNCT06794125

An Evaluation of Dose-escalation for Intrathoracic Tumours

A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)

Sponsor

Chris Goodman

Enrollment

141 participants

Start Date

Sep 3, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancers

Summary

This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether giving a higher dose of radiation — beyond the usual palliative amount — to tumors in the chest (such as lung cancer or other intrathoracic tumors) can better control the cancer and relieve symptoms without causing more side effects. **You may be eligible if...** - You are 18 or older with a tumor in the chest requiring palliative radiation - Your cancer is either causing symptoms or expected to cause symptoms within 6 months - Your overall health status is adequate (ECOG 0–3) - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have previously received thoracic (chest) radiation and delivering more would not be safe - You have serious medical conditions that make radiation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONHypofractionated Radiation Therapy

Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy

RADIATIONRadiation Therapy

standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy

Locations(3)

British Columbia Cancer Agency Center for the Southern Interior

Kelowna, British Columbia, Canada

London Health Sciences Center Research Institute (Formerly Lawson Research Institute)

London, Ontario, Canada

Waterloo Regional Health Network

Waterloo, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06794125

Related Trials

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

NCT068161211 location

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

NCT068103751 location